Drugs / IMA910
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00785122 | Jun 2008 → Jan 2011 | colorectal carcinoma | Immatics Biotechnologies GmbH | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-01-24 | Immatics Biotechnologies GmbH | immatics presents positive Phase II results with its therapeutic cancer vaccine IMA910 in patients with advanced colorectal cancer at the ASCO Gastrointestinal Cancers Symposium immatics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMA910 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00785122 ↗ |
| Modality | Vaccine | “the tumour multi-peptide vaccine IMA910” NCT00785122 ↗ |